Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN - 11/06/24
, Adam J. Nelson, MBBS, MBA, MPH, PhD a, Marc Ditmarsch, MD b, John J.P. Kastelein, MD, PhD b, Christie M. Ballantyne, MD c, Kausik K. Ray, MD, MPhil, FMedSci d, Ann Marie Navar, MD e, Steven E. Nissen, MD f, Anne C. Golberg, MD g, Liam R. Brunham, MDPhD h, Danielle Curcio, MBA b, Erin Wuerdeman, MS b, Annie Neild, PhD b, Douglas Kling, MBA b, Andrew Hsieh, PharmD b, Mary R. Dicklin, PhD i, Brian A. Ference, MD, MPhil, MSc j, Ulrich Laufs, MD, PhD k, Maciej Banach, MD, PhD l, Roxana Mehran, MD m, Alberico L. Catapano, PhD, MD HC n, o, Michael H. Davidson, MD bABSTRACT |
Background |
Obicetrapib, a novel, selective cholesteryl ester transfer protein (CETP) inhibitor, reduces low-density lipoprotein cholesterol (LDL-C), LDL particles, apolipoprotein (Apo) B, and lipoprotein(a) [Lp(a)] and increases high-density lipoprotein cholesterol (HDL-C) when added to statins with or without ezetimibe. By substantially reducing LDL-C, obicetrapib has the potential to lower atherogenic lipoproteins in patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) whose LDL-C levels remain high despite treatment with available maximally tolerated lipid-modifying therapies, addressing an unmet medical need in a patient population at high risk for cardiovascular events.
Methods and results |
BROADWAY (NCT05142722) and BROOKLYN (NCT05425745) are ongoing placebo-controlled, double-blind, randomized Phase III trials designed to examine the efficacy, safety, and tolerability of obicetrapib as an adjunct to dietary intervention and maximally tolerated lipid-modifying therapies in participants with a history of ASCVD and/or underlying HeFH whose LDL-C is not adequately controlled. The primary efficacy endpoint was the percent change in LDL-C from baseline to day 84. Other endpoints included changes in Apo B, non-HDL-C, HDL-C, Apo A1, Lp(a), and triglycerides in addition to parameters evaluating safety, tolerability, and pharmacokinetics. BROADWAY also included an adjudicated assessment of major adverse cardiovascular events, measurements of glucose homeostasis, and an ambulatory blood pressure monitoring substudy. A total of 2,532 participants were randomized in BROADWAY and 354 in BROOKLYN to receive obicetrapib 10 mg or placebo (2:1) for 365 days with follow-up through 35 days after the last dose. Results from both trials are anticipated in 2024.
Conclusion |
These trials will provide safety and efficacy data to support the potential use of obicetrapib among patients with ASCVD or HeFH with elevated LDL-C for whom existing therapies are not sufficiently effective or well-tolerated.
Le texte complet de cet article est disponible en PDF.Plan
Vol 274
P. 32-45 - août 2024 Retour au numéro
Article précédent
- A randomized clinical trial of catheter ablation and antiarrhythmic drug therapy for suppression of ventricular tachycardia in ischemic cardiomyopathy: The VANISH2 trial
- John L. Sapp, Anthony S.L. Tang, Ratika Parkash, William G. Stevenson, Jeff S. Healey, George Wells
- Rationale and design of a single-center randomized trial to compare the graft patency between the radial artery and the no-touch saphenous vein in coronary artery bypass grafting surgery (GRAFT-CAB Study)
- Fengqing Zhang, Meice Tian, Xiaohu Wang, Haotian Zhang, Xingtong Zhou, Rui Liu, Rui Liu, Zejian Jin, Changwei Zhang, Xianqiang Wang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?